Achieve Life Sciences Inc. has presented its corporate presentation outlining its strategic approach to addressing nicotine dependence, a significant public health crisis. The company plans to file a New Drug Application (NDA) for smoking cessation in June 2025, with an anticipated launch in the third quarter of 2026. Additionally, Achieve is pursuing a vaping cessation indication under the FDA Breakthrough Therapy designation and Priority Review, contingent on financing. The presentation highlights the company's competitive advantage with a differentiated and well-tolerated product profile, alongside a favorable payor environment, including anticipated Affordable Care Act coverage. Achieve aims to leverage innovative, data-driven solutions to drive product adoption and future growth. You can access the full presentation through the link below.